HY-16209-25mg
|
MedChemexpress LLC
|
Forodesine (hydrochloride) [CAS 284490-13-7]
|
|
Cancer-programmed cell death
|
|
HY-16209-5mg
|
MedChemexpress LLC
|
Forodesine (hydrochloride) [CAS 284490-13-7]
|
|
Cancer-programmed cell death
|
|
HY-16209-50mg
|
MedChemexpress LLC
|
Forodesine (hydrochloride) [CAS 284490-13-7]
|
|
Cancer-programmed cell death
|
|
HY-16210-1mg
|
MedChemexpress LLC
|
Forodesine [CAS 209799-67-7]
|
|
Cancer-programmed cell death
|
|
HY-16210-10mg
|
MedChemexpress LLC
|
Forodesine [CAS 209799-67-7]
|
|
Cancer-programmed cell death
|
|
HY-16210-25mg
|
MedChemexpress LLC
|
Forodesine [CAS 209799-67-7]
|
|
Cancer-programmed cell death
|
|
HY-16210-5mg
|
MedChemexpress LLC
|
Forodesine [CAS 209799-67-7]
|
|
Cancer-programmed cell death
|
|
HY-16210-50mg
|
MedChemexpress LLC
|
Forodesine [CAS 209799-67-7]
|
|
Cancer-programmed cell death
|
|
HY-W050088-1g
|
MedChemexpress LLC
|
Isoxepac [CAS 55453-87-7]
|
|
COVID-19-immunoregulation
|
|
HY-W050088-500mg
|
MedChemexpress LLC
|
Isoxepac [CAS 55453-87-7]
|
|
COVID-19-immunoregulation
|
|
HY-153360-1mg
|
MedChemexpress LLC
|
MC-GGFG-AM-(10Me-11F-Camptothecin) [CAS 2873460-70-7]
|
|
Cancer-programmed cell death
|
|
HY-153360-10mg
|
MedChemexpress LLC
|
MC-GGFG-AM-(10Me-11F-Camptothecin) [CAS 2873460-70-7]
|
|
Cancer-programmed cell death
|
|
HY-153360-5mg
|
MedChemexpress LLC
|
MC-GGFG-AM-(10Me-11F-Camptothecin) [CAS 2873460-70-7]
|
|
Cancer-programmed cell death
|
|